课题基金 / 基金详情

项目摘要

项目成果

Harry P. Selker的其他基金

相似基金

相关文献

中文摘要
翻译
在过去的10年里,塔夫茨临床和转化科学研究所(CTSI)汇集了
英文摘要
Over its 10 years, Tufts Clinical and Translational Science Institute (CTSI) has brought together purposefully-selected partners and has organized new and existing programs and activities with a singular purpose to best contribute to clinical and translational research (CTR). We focus on what we are best suited to do, based on our particular skills, resources, partners, and opportunities. Thereby, we have been able to provide unique and outstanding services, resources, education, and mentorship, locally, nationally, and to the field of CTR. With this application, we are pleased to be able to substantially grow our offerings by expanding our long-standing partners’ contributions, and by adding the special assets of new partners. With growth, our guiding principles have not changed: 1) We actively support the full spectrum of translational research, and we insist that wherever on the T1-T4 continuum, CTR must have a clear line of sight to potential ultimate impact on health; 2) At all stages of research, we practice “broadly-engaged team science.” For CTR to be relevant and impactful, research teams must have a wide array of stakeholders from inception to completion and dissemination; 3) We are active collaborators. We embrace our role as “the extrovert CTSA.” We believe that connections among diverse disciplines, stakeholders, and organizations are synergistic on many levels. This has powered our hub, and our leadership of multiple CTSA Consortium activities; 4) We believe that only by having systems and processes to continually assess and to iteratively improve processes will we achieve CTR excellence. We have a signature program in research process improvement, which we apply across CTR, and which led to our leading the national roll-out of the CTSA Common Metrics; 5) We reflexively look for opportunities to contribute novel research methods. Development, demonstration, and dissemination of new methods and approaches are hallmarks of our work, regardless of domain; 6) Rigorous role-specific education and training are fundamental to excellence in, and advancing, CTR. In service of these principles, our aims are: Overall AIM 1) Create an environment, resources, and services to stimulate and support the full spectrum of CTR by leveraging the diverse expertise and assets of Tufts CTSI partners. Overall AIM 2) Cultivate broadly-engaged team science, actively including stakeholders, to promote relevant and impactful translation for diverse populations and across the lifespan. Overall AIM 3) Develop, demonstrate, and disseminate innovations in methods, research process improvement, and evaluation, to advance CTR locally and nationally. Overall AIM 4) Advance methods and performance of multi-site clinical trials, within the Tufts CTSI Clinical Research Network, the NCATS Trial Innovation Network, and in other multi-institutional networks. Overall AIM 5) Provide outstanding education, training, and mentoring, tailored to different roles and disciplines, to advance a diverse CTR workforce, and share these resources nationally.
期刊论文(151)
专著(0)
科研奖励(0)
会议论文
DOI: 10.3390/molecules28155891
发表时间: 2023-08-05
期刊: Molecules (Basel, Switzerland)
影响因子: --
作者: [Alt-Holland A, Huang X, Mendez T, Singh ML, Papas AS, Cimmino J, Bairos T, Tzavaras E, Foley E, Pagni SE, Baleja JD]
通讯作者: Baleja JD
DOI: 10.1017/cts.2020.517
发表时间: 2020-07-28
期刊: Journal of clinical and translational science
影响因子: 2.6
作者: [Welch LC, Tomoaia-Cotisel A, Noubary F, Chang H, Mendel P, Parajulee A, Fenwood-Hughes M, Etchegaray JM, Qureshi N, Chandler R, Selker HP]
通讯作者: Selker HP
DOI: 10.1080/14636778.2022.2091532
发表时间: 2022
期刊: NEW GENETICS AND SOCIETY
影响因子: 1.8
作者: [Darling, Katherine Weatherford, Kohut, Michael, Leeds, Susan, Anderson, Eric C., Han, Paul K. J.]
通讯作者: Han, Paul K. J.
DOI: 10.1089/apc.2021.0060
发表时间: 2021-09
期刊: AIDS patient care and STDs
影响因子: 4.9
作者: [Dong KR, Daudelin DH, Koutoujian PJ, Cabrera A, Pezzullo O, Grossman A, Siddiqi K, Khorasani S, Wurcel AG]
通讯作者: Wurcel AG
109
    Tufts Clinical and Translational Science Institute (Clinical Trial Design Labs Supplement)
    • 批准号:
      10844980
    • 项目类别:
    • 资助金额:
      $97.51万
    • 财政年份:
      2023
    • 负责人:
      Harry P. Selker
    • 依托单位:
    Tufts Clinical and Translational Science Institute
    • 批准号:
      10622002
    • 项目类别:
    • 资助金额:
      $1139.42万
    • 财政年份:
      2023
    • 负责人:
      Harry P. Selker
    • 依托单位:
    Tufts Clinical and Translational Science Institute
    • 批准号:
      9816143
    • 项目类别:
    • 资助金额:
      $13.45万
    • 财政年份:
      2018
    • 负责人:
      Harry P. Selker
    • 依托单位:
    Tufts Clinical and Translational Science Institute
    • 批准号:
      10159334
    • 项目类别:
    • 资助金额:
      $943.36万
    • 财政年份:
      2018
    • 负责人:
      Harry P. Selker
    • 依托单位:
    海外基金